Bone Biologics Signs Option to License Nell-1 Bone Growth Factor for Use in Osteoporosis
Bone Biologics signed an option agreement with UCLA for an opportunity to exclusively license the use of Nell-1 bone growth factor in the treatment of osteoporosis.
Bone Biologics is presently funding the development of a Nell-1-based bone graft substitute for spinal fusion, also under exclusive license from UCLA. Nell-1 has demonstrated an ability to target bone formation with a high degree of safety, suggesting it to be an attractive treatment modality vs. other bone growth factors and implanted devices.
Sources: Bone Biologics Corporation, ORTHOWORLD Inc.